ERBB2 and breast cancer: A study analyzing HER2 protein expression in patients with locally advanced breast cancers who received neoadjuvant chemotherapy (n = 39) and patients who did not receive chemotherapy (n = 60) reported that the HER2 IHC scores significantly reduced in patients who received therapy (28.5%) compared to those who did not (11.7%) [185].